An international study on efficacy and safety of I10E in CIDP patients
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)MedDRA version: 18.0Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2013-005557-73-FR
- Lead Sponsor
- FB BIOTECHNOLOGIES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 44
1. Male or female patient aged 18 years or more.
2. - Definite or probable CIDP according to the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) guidelines 2010 clinical and neurophysiological criteria.
- Pure motor CIDP, provided that a diagnosis of multifocal motor neuropathy has been ruled out.
- CIDP associated with monoclonal gammopathy of undetermined significance (MGUS), provided that anti-MAG antibodies titer is lower than the used technique's negativity threshold (1000 BTU for Bühlmann ELISA technique).
- Lewis-Sumner syndrome.
3. Score of at least 2 on the adjusted INCAT disability scale.
4. Patient who either :
a) has never been previously treated with Ig (Ig-naive patient)
Or
b) was previously treated with Ig but is in clinical relapse following treatment withdrawal. In the latter case, the last Ig course shall have been administered no less than 3 months prior to screening.
5. Covered by national healthcare insurance system as required by local regulations.
6. Written informed consent obtained prior to any study-related procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 38
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4
1. History of severe allergic reaction or serious adverse reaction to any immunoglobulin (Ig).
2. Clinically documented lack of response to previous Ig treatment.
3. History of IgA deficiency, unless the absence of anti-IgA antibodies has been documented.
4. Known hypersensitivity to human Ig or to any of the excipients of I10E (glycine and polysorbate 80).
5. History of cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmia, unstable ischemic heart disease, or uncontrolled
hypertension.
6. History of venous thrombo-embolic disease, myocardial infarction or, cerebrovascular accident.
7. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematologic malignancy with monoclonal gammopathy.
8. History of personal or familial congenital thrombophilia or acquired thrombophilia.
9. Factors contributing to venous stasis such as long-term bed confinement.
10. Body mass Index (BMI) =40 kg/m².
11. Protein-losing enteropathy characterised by serum protein levels <60 g/L and serum albumin levels <30 g/L or nephrotic syndrome characterised by proteinuria =3.5 g/24hours, serum protein levels <60 g/L and serum albumin levels <30 g/L.
12. Glomerular filtration rate <80 mL/min/1.73m² measured according to the Modified Diet in Renal Disease (MDRD) calculation.
13. Serum levels of alanine aminotransferase (AST) or aspartate aminotransferase (ALT), >2 times upper limit of normal range.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective of this study is to assess the efficacy of I10E in improving the disability of patients with CIDP.<br><br>;Secondary Objective: The secondary objective is to assess the safety of I10E in patients with CIDP. <br>;Primary end point(s): Responder rate at EOS visit.<br>Responders are defined as patients with a decrease =1 point in the<br>adjusted INCAT score between baseline and the EOS visit.;Timepoint(s) of evaluation of this end point: at baseline and the End Of Study visit.
- Secondary Outcome Measures
Name Time Method Secondary end point(s): - Responder rate at 12 weeks.<br>- Time to response.<br>- Percentage of patients at 12 weeks and EOS visit with no change in<br>CIDP treatment.<br>- Changes from baseline to 12 weeks and EOS visit in the following<br>scores:<br>• Adjusted INCAT score;<br>• Grip strength with the Martin vigorimeter in both hands;<br>• Rasch-built Overall Disability Scale (R-ODS);<br>• Patient and Investigator Clinical Global Impression (CGI);<br>• Medical Research Council (MRC) 12 muscles sum score (0 to 5) and Rasch-modified MRC (0 to 3).;Timepoint(s) of evaluation of this end point: Baseline, at 12 weeks and End of study visit